Matsu

[ヒロ｜AI×LINEで自動収益化＠フォロバ１００％ @hirono_re]

ChatGPT・Claude・Gemini
全部で使える"神プロンプト15選"
まとめました。

コピペでそのまま使えるので
ブクマしておくと
明日からの作業マジで変わります。

[Jikei Urology @jikei_urology]

🎆London calling : 13 abstracts from the Team Jikei Urology have been accepted by the EAU 🇬🇧🇬🇧🇬🇧
See you in London!

@gehi87
@F_Urabe
@Macchan1055
@ene1the1r0nk1d

[Mehdi Kardoust Parizi @Mehdi_Kardoust]

Cannabis use and risk of testicular germ cell tumour: a systematic review and meta-analysis - Our findings highlight cannabis use as a significant modifiable risk factor for the development of TGCT, particularly NSGCT. https://t.co/zQyQQqogQn

[Matsu @Macchan1055]

Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Can... https://t.co/M5mDpuGLQo

[日本内視鏡外科学会 @jses_main]

JSESイラコン 17
📌下大静脈腫瘍塞栓を伴う右腎癌のロボット手術
📝下大静脈の遠位はステープリングし離断、肝臓を脱転し下大静脈は頭側でクランプ、さらにプリングル法で肝血流を制御し下大静脈を切開、腫瘍を直接確認して下大静脈ごと切除。この一連の手技を1枚のイラストで表現。
🖊Dr.Cazz
#JSESイラストコンテスト　#JSES_illustration_contest

[Navid Roessler @n_roessler]

📊 PARPi show no clinically meaningful deterioration in health-related quality of life in mCRPC.

🔍 This meta-analysis underscores the critical need for nuanced interpretation of HRQoL data in the palliative setting.

👉🏼 https://t.co/TMBzFpOyrZ

[Navid Roessler @n_roessler]

Local radiotherapy doesn’t improve OS in mHSPC patients, but significantly prolongs time to ADT resistance.

Redefining selection criteria is key to identify those who truly benefit in the era of next-generation imaging and modern systemic therapies.

https://t.co/2mQXfN41XI

[Eur Urol Focus @EurUrolFocus]

What is the role of #PSA response in androgen receptor pathway inhibitors (#ARPI)?

https://t.co/3gvWYyYGKl

@DrShariat @amerseburger @Albert0Briganti @dr_rajwa @Silke_Gillessen

[Shingo Hatakeyama @ShingoHatakeya1]

We are happy to share our recent publication,
"Effects of the NAC and Adjuvant Chemotherapy on the Prognosis of MIBC Treated With Radical Cystectomy".
Our findings showed that 3 or more NAC cycles plus AC may have limited effects on OS in MIBC patients who received RC.

[Shingo Hatakeyama @ShingoHatakeya1]

続き
②NACの使用率における日本の常識は56.1%（日本の泌尿器科医は優秀!）、術後補助化学療法は26.9％
③NAC2コースも3コースも効果が変わらなかった
④NAC後の術後補助化学療法は上乗せ効果が弱い可能性（今は術後補助免疫療法が標準です）
https://t.co/OvLfCWy7BL… https://t.co/F75eDPIhN4

[Marcin Miszczyk @miszczyk_marcin]

Very happy to share our recent meta-analysis on perirectal spacers in patients treated with radiotherapy for prostate cancer! https://t.co/07hpCTSnGU
@rstando @GiulioFrancoli1 @CZamboglou @agata_suleja @fazekasMD @Macchan1055 @mleapman @dr_rajwa @stephane_supiot @DrShariat

[Jeremy Teoh @jteoh_hk]

The #UroSoMe dinner! Fun group of urologists from all around the world joining hands to do meaningful work together! #EAU25

[Jeremy Teoh @jteoh_hk]

What a great meeting with the Global ERBT Registry team! Great preliminary results from >1700 patients. But we need more!! Let me know if you want to join. We will provide important data regarding the management alongside ERBT!! #ERBT #EAU25 #UroSoMe

[Stefano Mancon @ManconS_]

Impact of opium on bladder cancer incidence: A systematic review and m... https://t.co/MkXuc8Ags4

[Matsu @Macchan1055]

I'm happy to announce that I've been accepted into the YAU Prostate Cancer Working Group! 🤩 Excited to collaborate with YAU members on future research. 🔬🚀 @GMarra_MD @dr_rajwa

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟📢 @ASCO #GU25 | Abstract #17
🔬 LuPSMA + Enzalutamide improves OS & QoL in poor-risk mCRPC (ENZA-p trial).🌟
@drlouiseemmett @MartinStockler
📊 Key Findings (N=162, median FU: 34 months)
✅ OS: 34 vs. 26 months (HR 0.55, P=0.005)
✅ Improved deterioration-free survival at 12 months:

OHQL: 40% vs. 13% (P<0.001)
Physical function: 38% vs. 17% (P<0.001)
✅ Lower pain & fatigue scores until progression
📌 Clinical Impact:
🔹 LuPSMA + Enza enhances survival & QoL in poor-risk mCRPC.
🔹 Better symptom control with manageable toxicity.

👥 @APCCC_Lugano @OncoAlert @UroToday @GUOnc @PCFnews #ProstateCancer #mCRPC #GUcancer

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟📢 @ASCO #GU25 |
Abstract #658
🔬 Adjuvant nivolumab (NIVO) improves DFS & OS in muscle-invasive bladder cancer (MIBC) in CheckMate 274.
@MattGalsky
📊 Key Findings (N=560, FU: 36.1 months)
✅ DFS (NIVO vs. PBO)

All MIBC: 25.6 vs. 8.5 months (HR 0.63)
With prior NAC: 19.6 vs. 8.3 months (HR 0.58)
Without prior NAC: 25.9 vs. 13.7 months (HR 0.69)
✅ OS (NIVO vs. PBO)

All MIBC: NR vs. 39.9 months (HR 0.70)
PD-L1 ≥ 1%: NR vs. 37.6 months (HR 0.48)
With prior NAC: 55.2 vs. 40.2 months (HR 0.74)
📌 Clinical Impact:
🔹 Adjuvant NIVO remains the standard of care in high-risk MIUC & MIBC.
🔹 Potential curative option post-surgery.

👥 @ASCO @OncoAlert @UroToday @gu_onc @apolo_andrea @GUOncologyNow @MattMilowsky @ScotNiglio @XinanSheng @HouedeNadine @ERPlimackMD #BladderCancer #GUcancer #CheckpointInhibitors

[Matsu @Macchan1055]

How To Write a Response to Reviewers - ScienceDirect https://t.co/z38zGcKb6R

[UroToday.com @urotoday]

🧬 Preventing #ProstateCancer Progression During Active Surveillance 🧬

This systematic review/meta-analysis highlights the potential of nonsurgical interventions for prostate cancer patients on Active Surveillance:

5-alpha-reductase inhibitors (5-ARIs) ↓ risk of progression by 41%, without increasing treatment-related adverse events (TRAEs).
Mixed results for other therapies:
Effective: chlormadinone, FT inhibitors, enzalutamide, but with high TRAE rates ⚠️.
Limited benefit from lifestyle/diet interventions.
🔎 Challenges: Variability in biopsy protocols and PSA monitoring may skew findings.

Takeaway: Personalized strategies are crucial to optimize AS outcomes while minimizing risks.
Read Now > https://t.co/qQRU0yamsL @DrShariat @dr_rajwa

[UroToday.com @urotoday]

🧬 Preventing #ProstateCancer Progression During Active Surveillance 🧬

This systematic review/meta-analysis highlights the potential of nonsurgical interventions for prostate cancer patients on Active Surveillance:

5-alpha-reductase inhibitors (5-ARIs) ↓ risk of progression by 41%, without increasing treatment-related adverse events (TRAEs).
Mixed results for other therapies:
Effective: chlormadinone, FT inhibitors, enzalutamide, but with high TRAE rates ⚠️.
Limited benefit from lifestyle/diet interventions.
🔎 Challenges: Variability in biopsy protocols and PSA monitoring may skew findings.

Takeaway: Personalized strategies are crucial to optimize AS outcomes while minimizing risks.
Read Now > https://t.co/qQRU0yamsL @DrShariat @dr_rajwa